About US
Contact us
-
Japan authorities digging deeper into Novartis' use of flawed Diovan studySometimes saying you're sorry just isn't enough. Swiss drugmaker Novartis ($NVS)has repeatedly apologized after learning that a company employee was affiliated with a study in Japan of blockbusterDiov2013/9/29
-
Boehringer's China expansion hits as probes leave market in turmoilGermany'sBoehringer Ingelheimtwo years ago started on a major addition to its operations inChinaas that rapidly expanding market looked like the promised land to many drugmakers. But the new facilitie2013/9/29
-
Merck gives up on unsuccessful Januvia combo drug JuvisyncMerck ($MRK) may have some dark clouds hanging overhead, but its multibillion-dollar diabetes franchise can usually be counted on for a bit of shine. As it announced cuts to its full-year sales foreca2013/9/27
-
There is no mark on the production equipment to show the production status and equipment status.German drugmaker sees opportunity in biosims, allergy fighters Merck KGaA is rejigging its pharmaceuticals management. Hoping some integration will amp up growth in the drugs business, the Darmstadt,2013/9/27
-
FDA names Kashmir-born official to head India operationsAltaf Ahmed Lal takes on a 'daunting challenge' The FDA has selected Altaf Ahmed Lal, an Indian-born Ph.D., to take over management of its expanding operations inIndia. Lal says collaboration with In2013/9/26
-
CFDA requires carrying out registration and disclosure of drug clinical trial informationIn order to strengthen the supervision and management of drug clinical trials, promote the transparency of drug clinical trial information, and protect the rights, benefits and safety of trial subject2013/9/26
-
GlaxoSmithKline's China sales set for 30% hit, analysts figureAs third-quarter earnings season nears, analysts are totting up the potential losses in China. And for GlaxoSmithKline ($GSK), at the heart of the pharma bribery scandal there, the damage to sales may2013/9/25
-
Eli Lilly's diabetes strategy doesn't include big staff-up in salesDon't expect Eli Lilly to pump up its sales force as newdiabetes drugsmake their debuts over the next three years. As Lilly Diabetes President Enrique Conterno tellsBloomberg, the company ($LLY) plans2013/9/25
-
Novartis board to shrink executive pay, director saysNovartis board member Pierre Landolt let a couple of things slip in an interview with theBasler Zeitungpublished over the weekend. The first is a bit of a head-scratcher: Landolt would like the new ch2013/9/24
-
Indian drug regulator reaches out to other countries as issues mountThe top drug regulator inIndiahas decided it is time to confer with some of his peers around the world after a run of tough regulatory actions by Western countries against Indian drugmakers. Just last2013/9/24